The Global Biomedical Sensor Market is projected to grow from USD 10.79 Billion in 2024 to USD 20.95 Billion by 2032, at a CAGR of 15.87%. Growth is driven by increasing adoption of wearable health devices, rising prevalence of chronic diseases, and technological advancements in sensor miniaturization. However, stringent regulatory frameworks, high development costs, and data privacy concerns remain key challenges. North America dominates the market, while Asia-Pacific emerges as the fastest-growing region.
Medtronic plc (MDT)
Common Stock · Currency in USD · XNYS
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Company Info
SIC3845
Composite FIGI—
CIK0001613103
IPOJun 1, 1972
Sectorelectromedical & electrotherapeutic apparatus
Highlights
Market Cap$111.22B
EPS$4.28
P/E Ratio20.13
Revenue$35.08B
Gross Profit$23.60B
Net Income$5.52B
Employees95,000
WSO1,283,884,964
Phone01135314381700
Websitehttps://www.medtronic.com
Related Tickers
SYK
Stryker Corporation
$332.00 0.00%
ISRG
Intuitive Surgical Inc.
$454.29 0.00%
JNJ
Johnson & Johnson
$242.50 0.00%
ABT
Abbott Laboratories
$102.90 0.00%
BSX
Boston Scientific Corp.
$62.80 0.00%
NVST
Envista Holdings Corporation Common stock, $0.01 par value per share
$25.81 0.00%
DXCM
DexCom, Inc.
$63.00 0.00%
TMO
Thermo Fisher Scientific, Inc.
$489.90 0.00%
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Medtronic plc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Medtronic plc (MDT) has returned -9.80% so far this year and 6.66% over the past 12 months. Looking at the last ten years, MDT has achieved an annualized return of 1.33%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
MDT
1M-8.57%
6M-11.27%
YTD-9.80%
1Y6.66%
5Y-6.58%
10Y1.33%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Medtronic plc (MDT) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.21% | -5.05% | -10.77% | 0.06% | ||||||||
| 2025 | 13.00% | 1.94% | -3.03% | -4.54% | -1.45% | 5.79% | 3.93% | 3.57% | 2.92% | -4.68% | 16.19% | -8.51% |
| 2024 | 6.61% | -4.58% | 4.47% | -7.60% | 1.73% | -3.44% | 2.45% | 9.78% | 1.99% | -1.11% | -3.66% | -7.30% |
| 2023 | 7.34% | -1.43% | -2.16% | 13.19% | -8.88% | 6.35% | 0.24% | -6.64% | -4.57% | -9.42% | 12.41% | 4.16% |
| 2022 | 0.34% | 1.25% | 6.07% | -6.28% | -4.77% | -10.50% | 3.07% | -4.26% | -7.96% | 7.17% | -9.63% | -2.00% |
| 2021 | -5.01% | 3.83% | 0.11% | 10.54% | -3.92% | -3.08% | 5.50% | 1.46% | -6.57% | -4.87% | -11.19% | -4.89% |
| 2020 | 0.86% | -13.18% | -11.27% | 12.08% | 1.63% | -6.17% | 5.12% | 10.86% | -2.28% | -2.81% | 10.61% | 2.23% |
| 2019 | -1.27% | 1.83% | -0.11% | -3.08% | 4.23% | 4.97% | 3.71% | 5.92% | 1.29% | 0.06% | 2.01% | 2.02% |
| 2018 | 4.54% | -6.43% | 0.54% | 0.43% | 8.44% | -1.43% | 6.93% | 7.17% | 1.86% | -9.02% | 8.21% | -7.18% |
| 2017 | 8.21% | 7.48% | -0.92% | 2.77% | 1.53% | 4.89% | -5.44% | -4.15% | -3.63% | 3.15% | 2.13% | -2.07% |
| 2016 | 6.16% | 1.99% | 8.31% | 0.87% | -0.43% | -0.79% | -4.63% | -10.99% | -2.44% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Medtronic plc (MDT) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of MDT compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Medtronic plc volatility is 1.17%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 91.68B | 89.98B | 90.95B | 90.98B | 93.08B | 90.69B | 89.69B | 91.39B | 99.82B | 99.78B | 106.69B | 37.94B | 34.84B | 33.08B | 30.42B |
| Equity Attributable To Parent (USD) | 48.02B | 50.21B | 51.48B | 52.55B | 51.43B | 50.74B | 50.09B | 50.72B | 50.29B | 52.06B | 53.23B | 19.44B | 18.67B | 17.11B | 15.97B |
| Equity Attributable To Noncontrolling Interest (USD) | 232.00M | 206.00M | 182.00M | 171.00M | 174.00M | 135.00M | 121.00M | 102.00M | 122.00M | - | - | - | - | - | - |
| Equity (USD) | 48.26B | 50.42B | 51.67B | 52.72B | 51.60B | 50.87B | 50.21B | 50.82B | 50.42B | 52.06B | 53.23B | 19.44B | 18.67B | 17.11B | 15.97B |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.61B |
| Long-term Debt (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.13B |
| Noncurrent Liabilities (USD) | 30.55B | 28.77B | 30.23B | 25.87B | 32.97B | 29.45B | 31.01B | 30.49B | 35.18B | 40.55B | 44.28B | 12.94B | 12.28B | 10.11B | 9.74B |
| Other Current Liabilities (USD) | 10.43B | 8.38B | 6.39B | 10.12B | 6.40B | 8.37B | 6.52B | 8.46B | 12.49B | 5.46B | 7.56B | 4.82B | 3.27B | 5.29B | 4.20B |
| Accounts Payable (USD) | 2.45B | 2.41B | 2.66B | 2.28B | 2.11B | 2.00B | 1.95B | 1.63B | 1.73B | 1.71B | 1.61B | 742.00M | 622.00M | 565.00M | 511.00M |
| Current Liabilities (USD) | 12.88B | 10.79B | 9.05B | 12.39B | 8.51B | 10.37B | 8.47B | 10.08B | 14.22B | 7.17B | 9.17B | 5.56B | 3.89B | 5.86B | 4.71B |
| Liabilities (USD) | 43.42B | 39.56B | 39.28B | 38.26B | 41.48B | 39.82B | 39.48B | 40.57B | 49.40B | 47.72B | 53.46B | 18.50B | 16.17B | 15.97B | 14.46B |
| Other Non-current Assets (USD) | 49.36B | 48.69B | 48.86B | 46.91B | 47.57B | 44.77B | 42.49B | 42.09B | 47.18B | 44.44B | 43.04B | 12.06B | 11.89B | 18.45B | 16.02B |
| Intangible Assets (USD) | 11.67B | 13.23B | 14.84B | 15.60B | 17.74B | 19.06B | 20.56B | 21.72B | 23.41B | 26.90B | 28.10B | 2.29B | 2.67B | 2.65B | 2.78B |
| Fixed Assets (USD) | 6.84B | 6.13B | 5.57B | 5.41B | 5.22B | 4.83B | 4.68B | 4.60B | 4.36B | 4.84B | 4.70B | 2.39B | 2.49B | 2.47B | 2.51B |
| Noncurrent Assets (USD) | 67.87B | 68.05B | 69.27B | 67.92B | 70.54B | 68.66B | 67.73B | 68.41B | 74.94B | 76.18B | 75.84B | 16.73B | 17.05B | 23.57B | 21.31B |
| Other Current Assets (USD) | 18.34B | 16.72B | 16.38B | 18.44B | 18.24B | 17.80B | 18.21B | 19.40B | 21.54B | 20.13B | 27.38B | 19.49B | 16.08B | 7.72B | 3.60B |
| Inventory (USD) | 5.48B | 5.22B | 5.29B | 4.62B | 4.31B | 4.23B | 3.75B | 3.58B | 3.34B | 3.47B | 3.46B | 1.73B | 1.71B | 1.80B | 1.70B |
| Accounts Receivable (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.82B |
| Current Assets (USD) | 23.81B | 21.94B | 21.68B | 23.06B | 22.55B | 22.03B | 21.97B | 22.98B | 24.87B | 23.60B | 30.84B | 21.21B | 17.79B | 9.52B | 9.12B |
| Assets (USD) | 91.68B | 89.98B | 90.95B | 90.98B | 93.08B | 90.69B | 89.69B | 91.39B | 99.82B | 99.78B | 106.69B | 37.94B | 34.84B | 33.08B | 30.42B |
News and Insights
Stock Market Today, March 30: Boston Scientific Falls After Delivering Underwhelming Trial Resultsneutral
Boston Scientific shares fell 9.02% on March 30, 2026, after the company announced results from its CHAMPION-AF clinical trial for the Watchman FLX heart implant. While the trial met all safety and efficacy endpoints, analysts considered the results underwhelming and expressed concerns that growth may not accelerate as expected. Despite the decline, analysts maintained outperform ratings, noting the stock is reasonably valued at 18x forward earnings.
Intuitive Surgical faces near-term headwinds from tariffs and increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson. Despite trading at a premium valuation of 47.6x forward earnings, the company's strong competitive moat, expanding market opportunity, and consistent financial growth position it as an attractive long-term investment for buy-and-hold investors willing to tolerate near-term volatility.
Elon Musk announced Terafab, a $25 billion joint venture between Tesla, SpaceX, and XAI to build a vertically integrated semiconductor factory producing 1 terawatt of AI computing power annually. The facility aims to address supply chain bottlenecks and support Tesla's robotaxi and humanoid robot ambitions, plus SpaceX's orbital AI satellite constellation. While ambitious, industry experts question feasibility given the complexity of chip fabrication and Musk's mixed track record on delivery timelines.
Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.
The global surgical stapling devices market was valued at USD 5.47 billion in 2025 and is projected to reach USD 10.14 billion by 2035, growing at a 7.2% CAGR. Growth is driven by increasing surgical volumes, adoption of minimally invasive and robotic procedures, rising obesity and colorectal disease prevalence, and technological innovations in powered stapling systems. North America leads the market while Asia Pacific shows the fastest growth.
The global orthobiologics market is projected to grow from USD 6.68 billion in 2025 to USD 9.52 billion by 2031, with a CAGR of 6.17%. Growth is driven by rising osteoarthritis cases, sports-related injuries, and advancements in regenerative therapies including stem cell therapy and platelet-rich plasma treatments. North America leads the market while Asia-Pacific is the fastest-growing region.
The global personalized nutrition market is projected to grow from $15.79 billion in 2025 to $30.94 billion by 2030 at a 14.4% CAGR. Digital tools and active measurement technologies are the fastest-growing segments, while Asia Pacific emerges as a high-growth regional hub driven by expanding middle class, rising lifestyle diseases, and rapid digital health adoption.
Despite facing recent headwinds, Intuitive Surgical and DexCom are positioned for strong long-term growth. Intuitive Surgical benefits from aging population trends and a wide competitive moat despite new competition from Medtronic's Hugo system. DexCom has significant untapped market potential with millions of uninsured diabetes patients and expanding into non-diabetic markets with products like Stelo.
Medtronic announced a $550 million acquisition of Scientia Vascular to strengthen its neurovascular portfolio by integrating access and therapeutic solutions. The deal is expected to close in H1 fiscal 2027 and be minimally dilutive to adjusted EPS in 2027, becoming accretive thereafter. However, Medtronic shares declined 1.07% on the announcement as the stock trades below key moving averages with oversold RSI but bearish MACD momentum.